OncoMatch/Clinical Trials/NCT05103683
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
Is NCT05103683 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies TORL-1-23 for advanced solid tumor.
Treatment: TORL-1-23 — This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Ovarian Cancer
Endometrial Cancer
Non-Small Cell Lung Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: any cancer therapy
Exception: small molecule therapy within 14 days or biologic therapy within 28 days before first dose
Received prior chemotherapeutic, investigational, or other therapies for the treatment of cancer within 14 days with small molecule and within 28 days with biologic before the first dose of TORL-1-23
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Providence Medical Foundation · Fullerton, California
- UCLA - JCCC Clinical Research Unit · Los Angeles, California
- University of Kentucky Medical Center · Lexington, Kentucky
- University of Minnesota · Minneapolis, Minnesota
- Mayo Clinic in Rochester · Rochester, Minnesota
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify